no one gonna sell towards Pivotal Efficacy data expected by Q1 2017 w/possible near term partnership for both P2 osteoporosis & hypoglycemia(as mentioned by Co.) P2 Completed on both. $8m cap insane cheap for P2/P3 Co. w/$19m Cash on hand. a buck+ just a matter of time.imo A strong Ownership too. Risk/Reward ratio very impressive imo.
News 
Market Data 
Discover 
